Lyell Immunopharma Inc (LYEL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $11.01 (+1.94%), Market cap $0.54B, 52-week low–high $0.39 ~ $38.60.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate tha
Financial statements, price targets, institutional (13F) holdings and related news for Lyell Immunopharma Inc are updated in real time on BlackAll Trade.
Lyell Immunopharma Inc trades at $11.01 (+1.94%). Real-time quotes and charts are available on BlackAll Trade.
Lyell Immunopharma Inc has a market cap of about $0.54B.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The com